A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.

Baihua Zhang,Haifan Xiao,Xingxiang Pu,Chunhua Zhou,Desong Yang,Xu Li,Wenxiang Wang,Qin Xiao

Cancer medicine（2023）

引用 6|浏览9

暂无评分

摘要

Neoadjuvant chemoimmunotherapy for NSCLC is safe and feasible, with higher MPR rates, as well as favorable DFS than chemotherapy alone. Surgical complexity might be increased in certain patients, with comparable perioperative morbidity and mortality.

查看译文

关键词

chemoimmunotherapy,neoadjuvant therapy,non-small cell lung cancer,sleeve lobectomy,surgery

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要